Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for NOVOSEVEN
- SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
- Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
- Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects
- A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
- Treatment of Congenital Factor VII Deficiency
- Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
- Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
- Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
- Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery
- Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice
- Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage
- Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
- Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
- Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers
- Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation
- Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
- Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
- Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
- Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
- Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
- Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
- Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
- Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
- Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis
- Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency
- Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia
- Treatment of Inherited Factor VII Deficiency
- Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
- Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
- rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
- PROPACT: Retrospective Prophylaxis Patient Case Collection
- Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
- The Spot Sign for Predicting and Treating ICH Growth Study
- Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage
- Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
- Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
- Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
- High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors
- Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
- Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
- Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
- Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII
- Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
- Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
- The FEIBA NovoSeven Comparative Study
- Use of NovoSeven® in Active Variceal Bleeding
- Use of Activated Recombinant Human Factor VII in Cardiac Surgery
- Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)
- Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
- Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
- Trial of NovoSeven® in Haemophilia - Joint Bleeds
- Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
- Dose Response to Recombinant Factor VIIa When Administered for Bleed
Clinical trials list
click for details